Reimbursement of a second biosimilar infliximab could provide welcome savings in a health system struggling with high drug costs.
The Canadian province of British Columbia will now reimburse for Renflexis, a biosimilar infliximab, under its public drug plan, Merck has announced. The biosimilar is approved in Canada to treat a range of disorders, including inflammatory bowel diseases and inflammatory arthritis.
"We are pleased to see the government of British Columbia add Renflexis to its formulary, which offers effective and more affordable treatment options for patients impacted by these diseases," say Manon Lafontaine, vice president of patient access for Merck Canada, in a statement. "We're committed to continuing to work with provinces and territories throughout Canada to ensure broader access for all patients to the care they need."
The announcement follows the Canadian Agency for Drugs and Technologies in Health recommendation in February 2018 that the biosimilar be reimbursed for patients for whom infliximab is the most appropriate treatment option.
Read more about biosimilars in Canada.
Like the reference infliximab, Remicade, and another biosimilar, Inflectra, Renflexis has been classed as a Limited Coverage Drug in British Columbia, which means that it will not generally be considered for first-line therapy. Special criteria apply for the prescribing of infliximab in any of its approved indications through British Columbia’s PharmaCare drug coverage plan.
Reimbursement of a second biosimilar infliximab could provide welcome savings in a health system struggling with high drug costs; the latest annual report from Canada’s Patented Medicines Prices Review Board (PMPRB), released just last week, indicated that the average annual treatment cost for patients receiving brand-name infliximab grew from CaD $17,759 in 2006 (approximately US $13,708) to CaD $28,804 in 2017 (approximately US $22,234).
High-cost immunosuppressive biologics in general have seen a swift uptake in the Canadian market, driven primarily by brand-name Remicade, adalimumab (Humira), and etanercept (Enbrel), says the report. These products accounted for 4% of all patented medicine sales in 2008, but rose to 17% by 2017.
Renflexis is also approved by the FDA and is available in the United States.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.